TFAP2A

Across TCGA pan-cancer cohorts, TFAP2A mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TFAP2A data layer compared with 21 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TFAP2A mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated TFAP2A expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

HNSC, LSCC, and PDAC are the cancer types where TFAP2A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	II,III,IV	0.978	0.897	.011	9	view →
LSCC	DFS	Median	II,III,IV	1.000	0.841	.007	7	view →
PDAC	DFS	Median	II,III,IV	0.435	0.249	.011	6	view →
UCEC	DFS	Tertile	All	1.000	0.843	.024	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TFAP2A–HNSC (DFS)

Open the HNSC breakdown →